NXL
Nexalin Technology, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$2.36
+0.43%Year over year
Reported trailing growth
- Revenue
- +24.2%
- EBITDA
- -0.1%
- EBIT
- -1.2%
- EPS
- —
- Free cash flow
- -49.1%
- Operating cash flow
- -43.3%
Forward estimates
Based on analyst estimates
- Revenue
- +34.9%
- EBITDA
- +34.2%
- EPS
- +41.1%
Three-year CAGR
- Revenue
- -38.9%
- EBITDA
- -8.0%
- EBIT
- -8.2%
- Net income
- -8.1%
- EPS
- +39.8%
- Free cash flow
- -20.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026